ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.7602
-0.20%
Brent Oil
84.105
0.18%
Bitcoin
63,120.27
0.11%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Akebia Therapeutics Inc (AKBA)

  7. Akebia Therapeutics Inc (AKBA) Noticias

AKBA

Akebia Therapeutics (AKBA)

Akebia Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AKBA
FechaHoraFuenteTítuloSímboloCompañía
09/05/202416:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
09/05/202406:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKBAAkebia Therapeutics Inc
09/05/202406:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKBAAkebia Therapeutics Inc
09/05/202406:00PR Newswire (US)Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
02/05/202407:30PR Newswire (US)Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
01/05/202415:05PR Newswire (US)Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AKBAAkebia Therapeutics Inc
27/03/202419:26PR Newswire (US)Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on DialysisNASDAQ:AKBAAkebia Therapeutics Inc
14/03/202415:15PR Newswire (US)Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
11/03/202416:05PR Newswire (US)Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:AKBAAkebia Therapeutics Inc
29/02/202415:32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
30/01/202415:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKBAAkebia Therapeutics Inc
30/01/202407:00PR Newswire (US)Akebia Secures $55 Million Term Loan FinancingNASDAQ:AKBAAkebia Therapeutics Inc
18/01/202416:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
09/01/202407:30PR Newswire (US)Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial OfficerNASDAQ:AKBAAkebia Therapeutics Inc
20/12/202307:00PR Newswire (US)Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AKBAAkebia Therapeutics Inc
20/11/202307:00PR Newswire (US)Akebia Therapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:AKBAAkebia Therapeutics Inc
08/11/202306:30PR Newswire (US)Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
02/11/202315:30PR Newswire (US)Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon AdvisorsNASDAQ:AKBAAkebia Therapeutics Inc
31/10/202307:00PR Newswire (US)Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
25/10/202307:30PR Newswire (US)Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney DiseaseNASDAQ:AKBAAkebia Therapeutics Inc
18/10/202307:00PR Newswire (US)Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023NASDAQ:AKBAAkebia Therapeutics Inc
28/09/202307:00PR Newswire (US)Akebia Therapeutics Resubmits New Drug Application to the FDA for VadadustatNASDAQ:AKBAAkebia Therapeutics Inc
26/09/202307:00PR Newswire (US)Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial UpdateNASDAQ:AKBAAkebia Therapeutics Inc
06/09/202307:00PR Newswire (US)Akebia Therapeutics to Present at H.C. Wainwright Global Investment ConferenceNASDAQ:AKBAAkebia Therapeutics Inc
28/08/202307:55Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:AKBAAkebia Therapeutics Inc
25/08/202307:09PR Newswire (US)Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
24/08/202307:00PR Newswire (US)Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023NASDAQ:AKBAAkebia Therapeutics Inc
23/08/202315:35PR Newswire (US)Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
17/08/202315:05PR Newswire (US)Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023NASDAQ:AKBAAkebia Therapeutics Inc
10/08/202316:40PR Newswire (US)Akebia Therapeutics Provides Update on Form 10-Q FilingNASDAQ:AKBAAkebia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AKBA

Su Consulta Reciente

AMEX
XLE
Energy Select Sector SPDR
NYSE
JPM
JP Morgan Chase
NASDAQ
MSFT
Microsoft
NYSE
DIS
Walt Disney
SPI
SP500
S&P 500
USI
USTECH100
US Tech 100
AMEX
XLF
Financial Select Sector
NYSE
CVX
Chevron
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
MRK
Merck
FX
EURMXN
Euro vs MXN
USOTC
RHHBY
Roche (QX)
PM
XAUUSD
Gold vs US Dollar
AMEX
XLV
Health Care Select Sector
CCOM
OILBRENT
Brent Oil
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados